[{"address1": "500 Unicorn Park Drive", "address2": "Suite 303", "city": "Woburn", "state": "MA", "zip": "01801", "country": "United States", "phone": "781 222 9600", "website": "https://www.replimune.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.", "fullTimeEmployees": 331, "companyOfficers": [{"maxAge": 1, "name": "Mr. Philip  Astley-Sparke F.S.A.", "age": 52, "title": "Executive Chairman", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 960520, "exercisedValue": 0, "unexercisedValue": 435967}, {"maxAge": 1, "name": "Ms. Emily Luisa Hill", "age": 43, "title": "Chief Financial Officer", "yearBorn": 1980, "fiscalYear": 2024, "totalPay": 593047, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Konstantinos  Xynos M.B.A., M.D., Ph.D.", "age": 56, "title": "Chief Medical Officer", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 668686, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sushil  Patel Ph.D.", "age": 52, "title": "CEO & Director", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 665050, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert  Coffin Ph.D.", "age": 58, "title": "Founder, Chief Scientist & Director", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 785888, "exercisedValue": 0, "unexercisedValue": 5822722}, {"maxAge": 1, "name": "Mr. Andrew  Schwendenman", "age": 47, "title": "Chief Accounting Officer & Treasurer", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Sarchi", "age": 54, "title": "Chief Commercial Officer", "yearBorn": 1969, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Paul  Bullock", "title": "Chief Manufacturing Officer & Framingham Site Head", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1722470400, "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 2, "previousClose": 9.73, "open": 9.75, "dayLow": 9.2801, "dayHigh": 9.86, "regularMarketPreviousClose": 9.73, "regularMarketOpen": 9.75, "regularMarketDayLow": 9.2801, "regularMarketDayHigh": 9.86, "beta": 1.25, "forwardPE": -3.7923076, "volume": 391017, "regularMarketVolume": 391017, "averageVolume": 1182811, "averageVolume10days": 657260, "averageDailyVolume10Day": 657260, "bid": 9.79, "ask": 9.84, "bidSize": 100, "askSize": 200, "marketCap": 673648960, "fiftyTwoWeekLow": 4.92, "fiftyTwoWeekHigh": 21.32, "fiftyDayAverage": 9.1353, "twoHundredDayAverage": 8.4767, "currency": "USD", "enterpriseValue": 280474976, "floatShares": 43265890, "sharesOutstanding": 68321400, "sharesShort": 5895268, "sharesShortPriorMonth": 5739718, "sharesShortPreviousMonthDate": 1719532800, "dateShortInterest": 1722384000, "sharesPercentSharesOut": 0.0863, "heldPercentInsiders": 0.048299998, "heldPercentInstitutions": 0.88671, "shortRatio": 8.98, "shortPercentOfFloat": 0.125, "bookValue": 6.243, "priceToBook": 1.5793688, "lastFiscalYearEnd": 1711843200, "nextFiscalYearEnd": 1743379200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -220011008, "trailingEps": -3.27, "forwardEps": -2.6, "enterpriseToEbitda": -1.21, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "REPL", "underlyingSymbol": "REPL", "shortName": "Replimune Group, Inc.", "longName": "Replimune Group, Inc.", "firstTradeDateEpochUtc": 1532093400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ea19e92f-8d00-3fa8-9834-419bd79af5bf", "gmtOffSetMilliseconds": -14400000, "currentPrice": 9.86, "targetHighPrice": 17.0, "targetLowPrice": 12.0, "targetMeanPrice": 14.5, "targetMedianPrice": 14.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 469124000, "totalCashPerShare": 6.866, "ebitda": -231756992, "totalDebt": 75950000, "quickRatio": 13.286, "currentRatio": 13.462, "debtToEquity": 17.81, "returnOnAssets": -0.25742, "returnOnEquity": -0.46787, "freeCashflow": -117209000, "operatingCashflow": -186046000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-08-15"}]